Ray Dalio: Trump-Xi meeting to focus on trade, capital flows

Ray Dalio: Trump-Xi meeting to focus on trade, capital flows


Key Points
  • Ray Dalio, founder of hedge fund Bridgewater Associates, told CNBC he expects U.S. and Chinese leaders to find ways to work together.
  • He was speaking after an event in Shanghai in support of bilateral exchanges.
  • U.S. President Donald Trump is due to visit China next month, after postponing initial plans by several weeks due to the Iran war.



Source

Stocks making the biggest moves premarket: Delta Air Lines, Levi Strauss, Exxon Mobil & more
Finance

Stocks making the biggest moves premarket: Delta Air Lines, Levi Strauss, Exxon Mobil & more

Check out the companies making the biggest moves premarket: Delta Air Lines — Shares traded 12% higher, boosted by the steep declines in oil prices after the U.S. agreed to a ceasefire. The airline also posted better-than-expected results for the first quarter, though it issued second-quarter guidance that was below analyst estimates. Levi Strauss — […]

Read More
Stocks making the biggest moves premarket: Broadcom, UnitedHealth, Casey’s General Stores and more
Finance

Stocks making the biggest moves premarket: Broadcom, UnitedHealth, Casey’s General Stores and more

Check out the companies making headlines before the bell: Broadcom , Alphabet — Broadcom on Monday said it agreed to supply artificial intelligence chips for Google and signed an expanded deal with Anthropic to give the AI startup about 3.5 gigawatts worth of computing capacity from Google’s AI processors. Broadcom shares gained 3%, while Alphabet […]

Read More
Stocks making the biggest moves premarket: Netflix, Soleno Therapeutics, Strategy & more
Finance

Stocks making the biggest moves premarket: Netflix, Soleno Therapeutics, Strategy & more

Check out the companies making the biggest moves premarket: Netflix — The streaming platform climbed 1.5% after a Goldman Sachs upgrade to buy from neutral. The bank said it sees Netflix as continuing to be the leader in content acquisition and development, and a high chance for multiyear capital return back to shareholders. Soleno Therapeutics […]

Read More